Developing Biomarkers for Methamphetamine Addiction
Author Information
Author(s): Mendelson John, Baggott Matthew J, Flower Keith, Galloway Gantt
Primary Institution: Addiction and Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, St Luke’s Hospital
Hypothesis
Can biomarkers predict response to therapy or risk of relapse in methamphetamine addiction?
Conclusion
The study suggests that new, objective biomarkers like BDNF and quantitative measures of drug intake can improve understanding and treatment of methamphetamine addiction.
Supporting Evidence
- There are 11.7 million methamphetamine abusers in the U.S.
- BDNF levels are low in many addictive disorders but rise in recovering methamphetamine addicts.
- Current methods of measuring drug use are binary and do not quantify the amount used.
Takeaway
This study is about finding new ways to measure how much methamphetamine people use and how they recover from addiction, which can help doctors treat them better.
Methodology
The study uses innovative methods to quantify methamphetamine intake and measure BDNF levels in clinical trials.
Potential Biases
Potential biases in estimating drug use due to timing of urine sample collection and individual differences in metabolism.
Limitations
Results are ongoing and not yet presented, and the study may not account for all variables affecting BDNF levels.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website